184 related articles for article (PubMed ID: 18056197)
1. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.
Hassan R; Broaddus VC; Wilson S; Liewehr DJ; Zhang J
Clin Cancer Res; 2007 Dec; 13(23):7166-71. PubMed ID: 18056197
[TBL] [Abstract][Full Text] [Related]
2. Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts.
Hassan R; Williams-Gould J; Steinberg SM; Liewehr DJ; Yokokawa J; Tsang KY; Surawski RJ; Scott T; Camphausen K
Clin Cancer Res; 2006 Aug; 12(16):4983-8. PubMed ID: 16914588
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice.
Zhang Y; Xiang L; Hassan R; Paik CH; Carrasquillo JA; Jang BS; Le N; Ho M; Pastan I
Clin Cancer Res; 2006 Aug; 12(15):4695-701. PubMed ID: 16899620
[TBL] [Abstract][Full Text] [Related]
4. Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.
Filpula D; Yang K; Basu A; Hassan R; Xiang L; Zhang Z; Wang M; Wang QC; Ho M; Beers R; Zhao H; Peng P; Zhou J; Li X; Petti G; Janjua A; Liu J; Wu D; Yu D; Zhang Z; Longley C; FitzGerald D; Kreitman RJ; Pastan I
Bioconjug Chem; 2007; 18(3):773-84. PubMed ID: 17346030
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
Hassan R; Sharon E; Thomas A; Zhang J; Ling A; Miettinen M; Kreitman RJ; Steinberg SM; Hollevoet K; Pastan I
Cancer; 2014 Nov; 120(21):3311-9. PubMed ID: 24989332
[TBL] [Abstract][Full Text] [Related]
6. Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells.
Matsuzawa F; Kamachi H; Mizukami T; Einama T; Kawamata F; Fujii Y; Fukai M; Kobayashi N; Hatanaka Y; Taketomi A
BMC Cancer; 2021 Feb; 21(1):200. PubMed ID: 33637083
[TBL] [Abstract][Full Text] [Related]
7. Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.
Awuah P; Bera TK; Folivi M; Chertov O; Pastan I
Mol Cancer Ther; 2016 Jul; 15(7):1648-55. PubMed ID: 27196771
[TBL] [Abstract][Full Text] [Related]
8. Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model.
Fujii Y; Kamachi H; Matsuzawa F; Mizukami T; Kobayashi N; Fukai M; Taketomi A
Invest New Drugs; 2021 Oct; 39(5):1256-1266. PubMed ID: 33905019
[TBL] [Abstract][Full Text] [Related]
9. Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.
Zhang Y; Xiang L; Hassan R; Pastan I
Proc Natl Acad Sci U S A; 2007 Oct; 104(43):17099-104. PubMed ID: 17940013
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors.
Liu XF; Xiang L; FitzGerald DJ; Pastan I
Mol Cancer Ther; 2014 Jan; 13(1):82-9. PubMed ID: 24145282
[TBL] [Abstract][Full Text] [Related]
11. Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody.
Du X; Xiang L; Mackall C; Pastan I
Clin Cancer Res; 2011 Sep; 17(18):5926-34. PubMed ID: 21813632
[TBL] [Abstract][Full Text] [Related]
12. Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.
Leshem Y; O'Brien J; Liu X; Bera TK; Terabe M; Berzofsky JA; Bossenmaier B; Niederfellner G; Tai CH; Reiter Y; Pastan I
Cancer Immunol Res; 2017 Aug; 5(8):685-694. PubMed ID: 28674083
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine.
Kimura K; Sawada T; Komatsu M; Inoue M; Muguruma K; Nishihara T; Yamashita Y; Yamada N; Ohira M; Hirakawa K
Clin Cancer Res; 2006 Aug; 12(16):4925-32. PubMed ID: 16914581
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.
Kreitman RJ; Hassan R; Fitzgerald DJ; Pastan I
Clin Cancer Res; 2009 Aug; 15(16):5274-9. PubMed ID: 19671873
[TBL] [Abstract][Full Text] [Related]
15. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.
Weldon JE; Xiang L; Zhang J; Beers R; Walker DA; Onda M; Hassan R; Pastan I
Mol Cancer Ther; 2013 Jan; 12(1):48-57. PubMed ID: 23136186
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
Hassan R; Bullock S; Premkumar A; Kreitman RJ; Kindler H; Willingham MC; Pastan I
Clin Cancer Res; 2007 Sep; 13(17):5144-9. PubMed ID: 17785569
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.
Bauss F; Lechmann M; Krippendorff BF; Staack R; Herting F; Festag M; Imhof-Jung S; Hesse F; Pompiati M; Kollmorgen G; da Silva Mateus Seidl R; Bossenmaier B; Lau W; Schantz C; Stracke JO; Brinkmann U; Onda M; Pastan I; Bosslet K; Niederfellner G
Mol Oncol; 2016 Oct; 10(8):1317-29. PubMed ID: 27507537
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response.
Zhang J; Khanna S; Jiang Q; Alewine C; Miettinen M; Pastan I; Hassan R
Clin Cancer Res; 2017 Mar; 23(6):1564-1574. PubMed ID: 27635089
[No Abstract] [Full Text] [Related]
19. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma.
Hassan R; Viner JL; Wang QC; Margulies I; Kreitman RJ; Pastan I
J Immunother; 2000; 23(4):473-9. PubMed ID: 10916757
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
O'Reilly T; McSheehy PM; Wartmann M; Lassota P; Brandt R; Lane HA
Anticancer Drugs; 2011 Jan; 22(1):58-78. PubMed ID: 20890178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]